 Katja Aviszus
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocyte Subsets | 5 | 2020 | 75 | 0.930 |
Why?
| | Clonal Anergy | 5 | 2012 | 52 | 0.630 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2012 | 17 | 0.400 |
Why?
| | B-Lymphocytes | 10 | 2015 | 847 | 0.380 |
Why?
| | Antibody Formation | 2 | 2012 | 299 | 0.370 |
Why?
| | Immunologic Memory | 2 | 2007 | 369 | 0.280 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2007 | 40 | 0.280 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 5 | 2013 | 19 | 0.260 |
Why?
| | Self Tolerance | 3 | 2012 | 28 | 0.260 |
Why?
| | Immunoglobulin Variable Region | 7 | 2011 | 80 | 0.250 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 1042 | 0.230 |
Why?
| | Mice, Inbred A | 5 | 2012 | 49 | 0.210 |
Why?
| | Immunoglobulin G | 5 | 2017 | 886 | 0.210 |
Why?
| | Spleen | 3 | 2015 | 516 | 0.210 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 107 | 0.210 |
Why?
| | Cell Differentiation | 3 | 2007 | 1979 | 0.210 |
Why?
| | p-Azobenzenearsonate | 3 | 2012 | 4 | 0.180 |
Why?
| | Autoimmunity | 4 | 2013 | 907 | 0.180 |
Why?
| | Autoantigens | 3 | 2014 | 429 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 807 | 0.180 |
Why?
| | PPAR gamma | 1 | 2022 | 183 | 0.180 |
Why?
| | Adoptive Transfer | 4 | 2017 | 224 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2012 | 2182 | 0.170 |
Why?
| | Genes, Immunoglobulin | 4 | 2010 | 28 | 0.160 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2020 | 97 | 0.160 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2020 | 83 | 0.160 |
Why?
| | T-Lymphocyte Subsets | 2 | 2015 | 425 | 0.150 |
Why?
| | Berylliosis | 1 | 2020 | 185 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 654 | 0.140 |
Why?
| | Antibodies, Antinuclear | 3 | 2014 | 71 | 0.140 |
Why?
| | Mice | 17 | 2017 | 17843 | 0.130 |
Why?
| | Antigen-Antibody Complex | 1 | 2017 | 90 | 0.130 |
Why?
| | Receptors, Antigen, B-Cell | 3 | 2014 | 130 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2023 | 2193 | 0.120 |
Why?
| | Mice, Inbred C57BL | 6 | 2015 | 5792 | 0.120 |
Why?
| | Mutation | 3 | 2022 | 3964 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.120 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2010 | 257 | 0.120 |
Why?
| | Interleukin-4 | 1 | 2015 | 217 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 740 | 0.110 |
Why?
| | Haptens | 2 | 2007 | 22 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2017 | 1092 | 0.110 |
Why?
| | Autoantibodies | 3 | 2015 | 1501 | 0.110 |
Why?
| | Mice, Knockout | 4 | 2015 | 3020 | 0.100 |
Why?
| | Fatty Acid-Binding Proteins | 2 | 2023 | 71 | 0.100 |
Why?
| | Mice, 129 Strain | 1 | 2012 | 88 | 0.100 |
Why?
| | Immunoglobulin M | 1 | 2014 | 288 | 0.100 |
Why?
| | Hybridomas | 3 | 2007 | 237 | 0.100 |
Why?
| | Hemocyanins | 3 | 2007 | 62 | 0.090 |
Why?
| | Animals | 17 | 2017 | 37011 | 0.090 |
Why?
| | Germ-Line Mutation | 2 | 2005 | 172 | 0.090 |
Why?
| | Cells, Cultured | 3 | 2015 | 4206 | 0.090 |
Why?
| | Immunoglobulin kappa-Chains | 4 | 2011 | 20 | 0.090 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 187 | 0.080 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 282 | 0.080 |
Why?
| | Immune Tolerance | 2 | 2017 | 362 | 0.070 |
Why?
| | Lymphocyte Activation | 2 | 2004 | 1150 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 30 | 0.070 |
Why?
| | Antibodies, Monoclonal | 3 | 2017 | 1428 | 0.070 |
Why?
| | Antibody Affinity | 1 | 2007 | 60 | 0.070 |
Why?
| | CD40 Ligand | 1 | 2007 | 41 | 0.070 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2005 | 83 | 0.070 |
Why?
| | Antibody Specificity | 1 | 2007 | 189 | 0.070 |
Why?
| | Immunization, Secondary | 1 | 2007 | 89 | 0.070 |
Why?
| | Macrophages | 2 | 2022 | 1548 | 0.070 |
Why?
| | Peptide Fragments | 1 | 2011 | 708 | 0.070 |
Why?
| | Immunoglobulin mu-Chains | 2 | 2003 | 9 | 0.060 |
Why?
| | Antibody Diversity | 1 | 2005 | 16 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2615 | 0.060 |
Why?
| | Transgenes | 2 | 2003 | 180 | 0.060 |
Why?
| | Protein Binding | 2 | 2021 | 2229 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2007 | 778 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 118 | 0.050 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 55 | 0.050 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 88 | 0.040 |
Why?
| | CD11c Antigen | 1 | 2020 | 41 | 0.040 |
Why?
| | Receptors, Virus | 1 | 2021 | 83 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 117 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 665 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2001 | 171 | 0.040 |
Why?
| | Receptors, Fc | 1 | 2020 | 53 | 0.040 |
Why?
| | T-Box Domain Proteins | 1 | 2020 | 98 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 151 | 0.040 |
Why?
| | Receptors, Complement 3d | 1 | 2020 | 141 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2001 | 313 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 558 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2020 | 223 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 503 | 0.040 |
Why?
| | Gene Expression | 3 | 2014 | 1505 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2020 | 391 | 0.040 |
Why?
| | Oligonucleotides | 1 | 1999 | 149 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2002 | 488 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 367 | 0.030 |
Why?
| | Kinetics | 1 | 2021 | 1679 | 0.030 |
Why?
| | Binding Sites | 1 | 2021 | 1310 | 0.030 |
Why?
| | Base Sequence | 4 | 2003 | 2180 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2022 | 2838 | 0.030 |
Why?
| | Humans | 9 | 2023 | 137514 | 0.030 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 59 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2014 | 1185 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2005 | 2420 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2755 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 321 | 0.030 |
Why?
| | Germinal Center | 1 | 2015 | 58 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 240 | 0.030 |
Why?
| | Inflammation | 2 | 2022 | 2837 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2014 | 12 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2901 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2020 | 1167 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 414 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 413 | 0.030 |
Why?
| | Endocytosis | 1 | 2014 | 168 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3546 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 974 | 0.020 |
Why?
| | Radiation Chimera | 1 | 2011 | 30 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1227 | 0.020 |
Why?
| | Complementarity Determining Regions | 1 | 2010 | 51 | 0.020 |
Why?
| | Codon | 2 | 2002 | 90 | 0.020 |
Why?
| | Cell Membrane | 1 | 2014 | 751 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2011 | 368 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 309 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 337 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 10356 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2010 | 198 | 0.020 |
Why?
| | Arginine | 1 | 2010 | 274 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7593 | 0.020 |
Why?
| | snRNP Core Proteins | 1 | 2007 | 5 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2007 | 38 | 0.020 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2007 | 24 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1233 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2006 | 45 | 0.020 |
Why?
| | Receptors, Complement | 1 | 2006 | 123 | 0.020 |
Why?
| | Mice, Inbred NZB | 1 | 2005 | 16 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1999 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 501 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13243 | 0.010 |
Why?
| | Arsanilic Acid | 1 | 2003 | 1 | 0.010 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2003 | 12 | 0.010 |
Why?
| | Immunoglobulin Class Switching | 1 | 2003 | 20 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2003 | 155 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2003 | 345 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2005 | 1271 | 0.010 |
Why?
| | Epitopes | 1 | 2004 | 481 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2003 | 319 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2007 | 832 | 0.010 |
Why?
| | Chromatin | 1 | 2005 | 524 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2146 | 0.010 |
Why?
| | Cell Lineage | 1 | 2003 | 346 | 0.010 |
Why?
| | Immunoglobulin delta-Chains | 1 | 2001 | 2 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 401 | 0.010 |
Why?
| | Aged | 1 | 2020 | 23798 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2004 | 720 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4295 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 2001 | 118 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 269 | 0.010 |
Why?
| | Base Composition | 1 | 1999 | 77 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1770 | 0.010 |
Why?
| | Immunoglobulin Light Chains | 1 | 1999 | 47 | 0.010 |
Why?
| | Point Mutation | 1 | 2000 | 234 | 0.010 |
Why?
| | DNA Primers | 1 | 2000 | 514 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 33355 | 0.010 |
Why?
| | RNA Splicing | 1 | 2000 | 268 | 0.010 |
Why?
| | DNA Repair | 1 | 2000 | 230 | 0.010 |
Why?
| | Male | 2 | 2020 | 67718 | 0.010 |
Why?
| | Alleles | 1 | 2001 | 891 | 0.010 |
Why?
| | Adult | 1 | 2020 | 37821 | 0.010 |
Why?
| | Female | 2 | 2020 | 73162 | 0.010 |
Why?
| | Kidney | 1 | 2004 | 1472 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1999 | 720 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2000 | 1458 | 0.010 |
Why?
| | RNA | 1 | 2000 | 924 | 0.010 |
Why?
| | Biomarkers | 1 | 2001 | 4172 | 0.000 |
Why?
|
|
Aviszus's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|